Questions Remain Regarding PARP Inhibition in Recurrent Platinum-Sensitive Ovarian Cancer
January 11th 2021
Joshua G. Cohen, MD, FACOG, FACS, discusses the efficacy of PARP inhibitors in ovarian cancer, remaining questions regarding repeat inhibition and treatment duration, and the potential for combinations.